DaVita Clinical Research® (DCR), a Phase I-IV clinical trial research service business specializing in renal-related drug and device research and development for FDA approval, reports it...
DaVita Inc. announced that its Board of Directors has authorized an increase to its current stock repurchase program. The increase, together with previously available amounts, authorizes the...
DaVita Inc., a leading provider of kidney care services, announced it has been honored for the fourth consecutive year by Training Magazine as one of the Top 125 ranking companies of...
EL SEGUNDO, Calif., April 29 /PRNewswire-FirstCall/ DaVita Inc. today announced results for the quarter ended March 31, 2008. Net income for the three months ended March 31, 2008 was $86.9...
DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney failure and disease (CKD), and The Kidney TRUST™, which aims to increase awareness of CKD through...